Correlation of Tumor Immune Response with Prognosis in Node-Negative Breast Cancer Patients

Overview

Revise to include specific outcomes influenced by TILs and detail treatment regimens.

Background

Radiotherapy is a critical component of adjuvant treatment for breast cancer, significantly lowering local recurrence rates and enhancing survival. Recent trends favor hypofractionated regimens, which may offer similar efficacy with improved patient convenience. Understanding the role of immune markers, such as TILs, in this context is essential for optimizing treatment strategies.

Data Highlights

No numerical data available in the provided source material.

Key Findings

• High levels of TILs are associated with improved prognosis in node-positive breast cancer patients.
• In node-negative patients, TILs may predict differential benefits from hypofractionated radiotherapy regimens.
• Immune infiltration's prognostic value may vary based on estrogen receptor status.
• Previous studies show conflicting results regarding TILs' predictive value for radiotherapy benefits.
• The DBCG HYPO trial provides a contemporary context for evaluating immune markers in breast cancer treatment.

Clinical Implications

Clinicians should consider the levels of TILs when evaluating prognosis and potential treatment benefits in node-negative breast cancer patients. Tailoring radiotherapy approaches based on immune infiltration may enhance patient outcomes.

Conclusion

The study underscores the importance of immune markers in predicting treatment responses in breast cancer, highlighting the need for further research to refine therapeutic strategies.

References

1. Danish Breast Cancer Group, DBCG HYPO Trial, 2023 -- Correlation of Tumor Immune Response with Prognosis
2. The ASCO Post — Genomic Characteristics and Immune Infiltration in Triple-Negative Breast Cancer
3. The ASCO Post — Presence of Tumor-Infiltrating Lymphocytes Following Neoadjuvant Treatment May Contribute to Worse Survival in Patients With HER2-Positive Breast Cancer
4. The ASCO Post — ctDNA Positivity After Neoadjuvant T-DM1 May Predict HER2-Positive Breast Cancer Recurrence
5. asco ai in oncology — Transcriptomic Classifier for Predicting Neoadjuvant Immunotherapy Response in Triple-Negative Breast Cancer
6. Genomic Characteristics and Immune Infiltration in Triple-Negative Breast Cancer
7. Presence of Tumor-Infiltrating Lymphocytes Following Neoadjuvant Treatment May Contribute to Worse Survival in Patients With HER2-Positive Breast Cancer
8. ctDNA Positivity After Neoadjuvant T-DM1 May Predict HER2-Positive Breast Cancer Recurrence
9. Transcriptomic Classifier for Predicting Neoadjuvant Immunotherapy Response in Triple-Negative Breast Cancer
10. NCCN 2025 Breast Cancer Congress
11. Hypofractionated Whole-Breast Irradiation with Simultaneous Integrated Boost for Breast Cancer: Primary Analysis of the HYPOSIB-Trial (ARO 2013-05)
12. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer